Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 3/20 | 0.46 |
| ▸ | DRD2 | P14416 | 5/20 | 0.46 |
| ▸ | DRD5 | P21918 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 6/20 | 0.45 |
| ▸ | HTR1A | P08908 | 5/20 | 0.45 |
| ▸ | HTR7 | P34969 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14412214 | 0.92 | DRD3 (0.50) | CNR2DRD3DRD2DRD4ADRA1D | |
| SCHEMBL5449203 | 0.91 | HTR1A (0.49) | DRD3DRD2HTR1AHTR7LMNA | |
| SCHEMBL5448948 | 0.91 | CNR2 (0.47) | CNR2ADRA1D | |
| SCHEMBL5443962 | 0.90 | CNR2 (0.46) | CNR2DRD3DRD2DRD4MAPT | |
| Hydrochloric Acid SCHEMBL5472148 | 0.88 | CNR2 (0.44) | CNR2DRD3DRD2DRD4HTR1A | |
| SCHEMBL5448134 | 0.88 | CNR1 (0.55) | CNR2DRD3DRD2DRD5DRD4 | |
| Hydrochloric Acid SCHEMBL5454205 | 0.87 | ADRA1D (0.55) | CNR2DRD3DRD2DRD4HTR1A | |
| SCHEMBL5451251 | 0.84 | CNR2 (0.50) | CNR2ADRA1D | |
| SCHEMBL5456434 | 0.84 | CNR2 (0.51) | CNR2MAPT | |
| SCHEMBL5451043 | 0.84 | HTR1A (0.51) | CNR2HTR1AHTR7ADRA1DHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| WO-2007079239-A2 | BICYCLIC NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | CNR2 106/4885DRD3 2993/4885DRD2 2688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.